

## Efficacy of biomarkers and personalized cancer therapeutics

A step forward to predicting efficacy of treatment in the individual patient

### Thursday, June 28

#### 08:15-08:30 OPENING

Welcome address: what has been accomplished and what do we need to address?

**Alexander Eggermont**, Director, Cancer Institute Gustave Roussy, France

#### 08:30-10:35 SESSION 1

FUNDAMENTAL CONCEPTS AND STRATEGIES TO IMPROVE EFFICACY OF THERAPEUTICS

Chairs: **Alexander Eggermont**, France; **John Mendelsohn**, USA

08:30 Shortening the timeline for cancer drug development

**James Doroshow**, Deputy Director for Clinical and Translational Research, National Cancer Institute, USA

08:55 Genome and the shift in therapeutic strategies

**Edison Liu**, President, Human Genome Organisation HUGO & President and CEO, Jackson Laboratory, USA

09:20 Optimizing the cancer drug development ecosystem

**Ronald DePinho**, President, University of Texas MD Anderson Cancer Center, USA

09:45 A biopharma company perspective

**Christopher A. Viehbach**, Chief Executive Officer, Sanofi

10:10 National and international strategies to improve efficacy

**Fabien Calvo**, Deputy Director, French National Cancer Institute / Institut National du Cancer (INCA), France

#### 10:35-11:00

COFFEE BREAK & NETWORKING

#### 11:00-13:00 SESSION 2

WIN CONSORTIUM – GLOBAL INNOVATIVE CLINICAL TRIALS

Chairs: **Rene Bernards**, The Netherlands; **John Quackenbush**, USA

11:00 WIN Consortium: Strategy, structure, mission and interactions with the community

**John Mendelsohn**, Chairman, WIN Consortium; Co-Director, Institute for Personalized Medicine, University of Texas MD Anderson Cancer Center, USA

11:20 A step forward for next generation sequencing and medical applications

**Mike Pellini**, President and Chief Executive Officer, Foundation Medicine, Cambridge, USA

11:40 WINTHER –WIN therapeutics clinical trial

**Jean-Charles Soria**, Head, Early Clinical Trials Program & Head Personalized Medicine, Cancer Institute Gustave Roussy, France

With the participation of:

**Razelle Kurzrock**, Chair, Phase I Program, University of Texas MD Anderson Cancer Center, USA

**Josep Tabernero**, Head, Medical Oncology Division, Val d'Hebron, Spain

**Raanan Berger**, Head, Medical Oncology Division, Chaim Sheba Medical Center, Israel

12:20 WIN Universal BioMarker (UBM) development and clinical trial

**Vladimir Lazar**, Chief Operating Officer, WIN Consortium & Head, Genomic Centre, Cancer Institute Gustave Roussy, France

**Sam Raha**, Vice President, Life Technologies, USA

12:40 WIN Biomarker Registry

**Fabrice Andre**, Head, Biomarker INSERM Unit, Cancer Institute Gustave Roussy, France

## 13:00-14:00

POSTER VIEWING, LUNCH & NETWORKING

## 14:00-16:05 SESSION 3

BIOLOGY-DRIVEN DIAGNOSTICS AND THERAPEUTICS - BIOMARKERS AND THEIR INTENDED USES:  
DIAGNOSTICS AND DRUG DEVELOPMENT

Chairs: **James Doroshow**, USA; **Leroy Hood**, USA

14:00 The challenges of drug-diagnostic co-development: A biopharmaceutical perspective

**Steven Averbuch**, Vice President, Early Global Clinical Research Oncology & Head, Pharmacodiagnosics, Bristol-Myers Squibb, USA

14:25 Biomarkers and therapeutic decision making

**Rene Bernards**, Head, Division Molecular Carcinogenesis, Netherlands Cancer Institute, The Netherlands

14:50 Biomarkers and drug combinations

**Paolo Paoletti**, Vice President, Head Oncology R & D, GlaxoSmithKline Oncology, USA

15:15 Role of biomarkers in the development of targeted cancer therapeutics

**Richard Gaynor**, Vice President, Oncology Clinical Development and Medical Affairs, Eli Lilly and Company, USA

15:40 Asian cancer genomics: Novel diagnostic and therapeutic targets

**Bin Tean Teh**, SingHealth Group Director for Translational Research, Singapore

## 16:05-16:30

COFFEE BREAK & NETWORKING

## 16:30-18:10 SESSION 4

COMBINATORIAL BIOMARKERS AND EFFICACY OF THERAPEUTICS

Chairs: **Ronald DePinho**, USA; **Jean-Charles Soria**, France

16:30 The evolution of the BATTLE trials in lung cancer

**Waun Ki Hong**, Head, Medical Division, University of Texas MD Anderson Cancer Center, USA

16:55 Biomarkers for immuno-oncology therapies: Translating tumor-host networks

**Jeffrey Jackson**, Group Director, Oncology Biomarkers, Bristol-Myers Squibb, USA

17:20 No cure without anticancer immune responses: a rising paradigm

**Laurence Zitvogel**, Head, Immuno-Oncology, Cancer Institute Gustave Roussy, France

## 17:45-18:00 PATIENT ADVOCACY ORGANIZATIONS

- 17:45 Early detection of cancers and patient education  
*Janelle Hail, President, National Breast Cancer Foundation, USA*

## 18:00-19:00

WELCOME RECEPTION

## Evening

GALA DINNER (ticketed)

## Friday, June 29

### 08:30-10:35 SESSION 5

INNOVATIVE TARGETS AND NEW DRUG DISCOVERIES

*Chairs: Richard Gaynor, USA; Josep Tabernero, Spain*

- 08:30 Translating scientific innovation into patient benefit  
*Christian Meisel, Head, Translational Medicine Penzberg, Roche, Germany*
- 08:55 Drugging the cancer genome: Opportunities and challenges  
*Paul Workman, Deputy Chief Executive and Head of Cancer Therapeutics, The Institute of Cancer Research, UK*
- 09:20 Building an information platform for new drug discovery  
*William Dalton, President, Lee Moffitt Cancer Center, USA*
- 09:45 Perspectives on personalised therapeutics.  
*Nick Botwood, Development Director, Late Oncology Portfolio, AstraZeneca, UK*
- 10:10 Lecture title tba  
*Elisabeth Mansfield, Director, Personalized Medicine, Food & Drug Administration, USA*

### 10:35-11:00

COFFEE BREAK & NETWORKING

### 11:00-13:05 SESSION 6

INNOVATIVE THERAPEUTICS AND CLINICAL TRIALS

*Chairs: Nick Botwood, UK; Richard L. Schilsky, USA*

- 11:00 Personalized medicine trials: Are we ready for prime time?  
*Patricia LoRusso, Director, Phase I Clinical Trials Program, Barbara Ann Karmanos Cancer Institute, USA*
- 11:25 Biopsy-driven trials to identify biomarkers of therapeutic resistance: biospecimen collection and processing to enable multi-dimensional analysis  
*Gerald Batist, Professor of Oncology, McGill University & Director, Segal Cancer Center at the Jewish General Hospital, Canada*
- 11:50 Molecular characterization and pre-screening process in early drug clinical development of PI3K-pathway inhibitors  
*Josep Tabernero, Head, Medical Division, Val d'Hebron, Spain*
- 12:15 Arch2POCM: A PPP to de-risk drug development and better understand target mechanisms in the clinic  
*Stephen Friend, President, Sage Bionetworks, USA*

## WIN 2012 Symposium

June 28-29, 2012, Palais des Congrès, Paris, France

www.winconsortium.org



Worldwide Innovative Networking in  
personalized **cancer** medicine

---

12:40 Personalized phase I trials: What we have learned from the MD Anderson Initiative?  
**Razelle Kurzrock**, Chair, Phase I Program, University of Texas MD Anderson Cancer Center,  
USA

### 13:05-14:00

POSTER VIEWING, LUNCH & NETWORKING

### 14:00-15:00 SESSION 7

BEST POSTERS AWARDS AND ORAL PRESENTATIONS: EMERGING CONCEPTS, TECHNOLOGIES AND  
NEW TOOLS FOR EARLY DIAGNOSTIC AND THERAPEUTIC DECISION MAKING

Chairs: **Dingwey Ye**, China; **Amir Onn**, Israel

14:00 Award presentation: diagnostics  
14:15 Award presentation: therapeutics  
14:30 Award presentation: technologies and tool development  
14:45 Award presentation: computational / bioinformatics

### 15:00-17:00 SESSION 8

SYSTEM BIOLOGY AND BIOINFORMATICS

Chairs: **Stephen Friend**, USA; **Paul Workman**, UK

15:00 EGFR and HER2: prototype drug targets and mechanisms of patient resistance to EGFR and  
HER2 inhibitors  
**Yosef Yarden**, Department Biological Regulation, Weizmann Institute of Science, Israel  
15:30 Systems approaches to disease enable proactive P4 medicine  
**Leroy Hood**, President and co-founder, Institute for Systems Biology, USA  
16:00 Gene networks models, cell fate transitions, and the role of variation in defining phenotype  
**John Quackenbush**, Biostatistics and Computational Biology Cancer Biology, Center for  
Cancer Computational Biology at Dana-Farber Cancer Institute, Department of Biostatistics  
Harvard School of Public Health, USA  
16:30 WIN 2012 symposium synthesis and perspectives  
**Richard L. Schilsky**, Chairman WIN Scientific Advisory Board, University of Chicago, USA

### 17:00 -17:30 SESSION 9

OPEN DISCUSSION WITH ATTENDEES AND PRESS CONFERENCE

**John Mendelsohn**, Chairman WIN Consortium

**Richard L. Schilsky**, Chairman WIN Scientific Advisory Board

17:30 ADJOURN

---

### Contact

WIN 2012 Symposium Secretariat

*Congress by design*

P.O. Box 77 - 3480 DB Harmelen - The Netherlands

Phone: +31 88 089 8101

Fax: +31 88 089 8109

Email: win@congressbydesign.com